Scholarlink

<p>Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with immunotherapy proving effective only in a subset of patients, highlighting the urgent need for improved biomarkers and therapeutic targets. This study explored regulatory T cell (Treg) metabolism-related genes in NSCLC and established a seven-gene prognostic signature (TIMP1, BIRC3, G0S2, PRKCB, PDE4B, CD52, and ACP5) through multi-omics analysis. The model stratified patients into high- and low-risk groups exhibiting distinct immune profiles and drug sensitivities. Clinical validation confirmed that elevated BIRC3 and G0S2 expression correlated with poorer prognosis, while functional assays demonstrated that G0S2 inhibition suppressed tumour progression and reduced Treg infiltration in vivo. These findings position G0S2 as a promising biomarker for immunotherapy response and a potential therapeutic target, providing insights into Treg-mediated immune regulation and advancing personalized NSCLC treatment strategies.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

G0S2: a potential target for NSCLC identified through prognostic models from multi-Omic analysis of regulatory T cell metabolic genes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月19日

查看全文
  • Min Zhou,
  • Mengqing Liu,
  • Yile Hu,
  • Zhe Xu,
  • Lutong Cai,
  • Yunpeng Bai,
  • Lin Su,
  • Lei Sun

摘要

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with immunotherapy proving effective only in a subset of patients, highlighting the urgent need for improved biomarkers and therapeutic targets. This study explored regulatory T cell (Treg) metabolism-related genes in NSCLC and established a seven-gene prognostic signature (TIMP1, BIRC3, G0S2, PRKCB, PDE4B, CD52, and ACP5) through multi-omics analysis. The model stratified patients into high- and low-risk groups exhibiting distinct immune profiles and drug sensitivities. Clinical validation confirmed that elevated BIRC3 and G0S2 expression correlated with poorer prognosis, while functional assays demonstrated that G0S2 inhibition suppressed tumour progression and reduced Treg infiltration in vivo. These findings position G0S2 as a promising biomarker for immunotherapy response and a potential therapeutic target, providing insights into Treg-mediated immune regulation and advancing personalized NSCLC treatment strategies.